Literature DB >> 5472689

Serum levels of fibrin-fibrinogen degradation products in the haemolytic-uraemic syndrome.

W S Uttley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5472689      PMCID: PMC1647657          DOI: 10.1136/adc.45.242.587

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  7 in total

1.  Heparin therapy in the haemolytic-uraemic syndrome.

Authors:  G S Gilchrist; E Lieberman; H Ekert; R N Fine; C Grushkin
Journal:  Lancet       Date:  1969-06-07       Impact factor: 79.321

2.  A microhemagglutination-inhibition assay for the quantitation of fibrinogen breakdown products.

Authors:  E D Israels; H Rayner; L G Israels; A Zipursky
Journal:  J Lab Clin Med       Date:  1968-02

3.  Treatment of patients with microangiopathic haemolytic anaemia with heparin.

Authors:  M C Brain; L R Baker; J A McBride; M L Rubenberg; J V Dacie
Journal:  Br J Haematol       Date:  1968-12       Impact factor: 6.998

4.  Recognition and treatment of intravascular coagulation.

Authors:  C F Abildgaard
Journal:  J Pediatr       Date:  1969-02       Impact factor: 4.406

5.  Intravascular coagulation in an infant with the hemolytic-uremic syndrome.

Authors:  L Monnens; E Schretlen
Journal:  Acta Paediatr Scand       Date:  1967-07

6.  Fibrin degradation products in sera of normal subjects.

Authors:  P C Das; A G Allan; D G Woodfield; J D Cash
Journal:  Br Med J       Date:  1967-12-23

7.  Fibrin-fibrinogen degradation products in sera of normal infants and children.

Authors:  W S Uttley; A G Allan; J D Cash
Journal:  Arch Dis Child       Date:  1969-12       Impact factor: 3.791

  7 in total
  1 in total

1.  Coagulation studies in haemolytic uraemic syndrome.

Authors:  M L Willoughby; A V Murphy; S McMorris; F G Jewell
Journal:  Arch Dis Child       Date:  1972-10       Impact factor: 3.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.